Allergan and Sosei are voluntarily suspending clinical development activities with HTL0018318 pending investigation of an unexpected toxicology finding in an animal study involving non-human primates.
Read More
Heptares Therapeutics, the UK-headquartered wholly-owned subsidiary of Japan’s Sosei Group, has formed a new drug research and development pact with Imperial College London focused on gastrointestinal disease.
Read More
London, UK-based Heptares Therapeutics says the first healthy subject has now been dosed with its first-in-class, selective muscarinic M4 receptor agonist HTL0016878 in a Phase I clinical study.
Read More
